🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the battle against superbug strains of the bacteria, according to health experts.

An International Challenge

The sexually transmitted infection are escalating worldwide, with figures suggesting over 82 million infections each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the face of increasing worldwide cases, escalating drug resistance and the very limited treatment choices currently available.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Approval

One new antibiotic, also known as Nuzolvence, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization marks a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which uses an injection and a pill. The study involved nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in many developing nations.

Clinicians on the front lines have voiced optimism. Having a single-dose, oral treatment of this kind is seen as a "critical tool" for public health efforts. This is considered vital to alleviate the strain of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.